Pancreatic Cancer Research

ResearcherTezcat Biosciences, Inc.Active in the last 2 years

Dafna Bar‐Sagi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2597-8948; OpenAlex author ID A5056698491; NIH RePORTER profile ID 1894156. Sources: funder_awards.

Their work

Papers
16 (first author 0, last author 7)
Trials
0
Grants
4
Labs led
1
Collaborators
99
Papers, trials and grants by year

2008: 1 grant · 2009: none · 2010: none · 2011: none · 2012: none · 2013: none · 2014: 1 grant · 2015: 1 paper · 2016: none · 2017: 2 papers · 2018: none · 2019: none · 2020: 2 papers · 2021: 3 papers · 2022: 2 papers, 2 grants · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers

Papers 16

  1. Hepatocytes promote liver metastasis of pancreatic cancer by providing serine. Co-author DOI 10.1038/s41586-026-11051-z↗
  2. Selective targeting of NRF2-high pancreatic ductal adenocarcinoma with an NQO1-activatable prodrug. Co-author DOI 10.1073/pnas.2511733123↗
  3. Self-amplifying NRF2-EZH2 epigenetic loop converts KRAS-initiated progenitors to invasive pancreatic cancer. Co-author DOI 10.1038/s43018-025-01003-3↗
  4. Surgical Resection of Murine PDAC Alters Hepatic Metastases and Immune Microenvironment. Last author DOI 10.1097/mpa.0000000000002516↗
  5. Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the T… Co-author DOI 10.1158/2326-6066.cir-23-1073↗
  6. CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-22-2553↗
  7. Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer. Last author DOI 10.1016/j.ccell.2022.05.006↗
  8. Metabolic reprogramming of tumor-associated macrophages by collagen turnover promotes fibrosis in pancreatic cancer. Last author DOI 10.1073/pnas.2119168119↗
  9. Integrated Systems Analysis of the Murine and Human Pancreatic Cancer Glycomes Reveals a Tumor-Promoting Role for ST6GAL1. Co-author DOI 10.1016/j.mcpro.2021.100160↗
  10. A novel target for combination immunotherapy in pancreatic cancer: IL-1β mediates immunosuppression in the tumour microenvironment. Last author DOI 10.1038/s41416-021-01303-2↗
  11. Pancreatic cancer ductal cell of origin drives CD73-dependent generation of immunosuppressive adenosine Co-author DOI 10.1101/2021.11.29.470415↗
  12. Tumor Cell-Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-19-2080↗
  13. Selective Alanine Transporter Utilization Creates a Targetable Metabolic Niche in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-19-0959↗
  14. Crosstalk between Regulatory T Cells and Tumor-Associated Dendritic Cells Negates Anti-tumor Immunity in Pancreatic Cancer. Last author DOI 10.1016/j.celrep.2017.06.062↗
  15. Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer. Last author DOI 10.1158/2326-6066.cir-16-0125↗
  16. Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Co-author DOI 10.1158/0008-5472.can-14-2211↗

Grants 4

  1. Dectin-1 signaling drives pancreatic oncogenesis by inducing macrophage-mediated adaptive immune suppression R01CA215471↗
  2. A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer. R41CA265512↗
  3. PDA Development: Heads or Tails? AWARD pancan:2014-dafna-bar-sagi-phd-pda-development-heads-or-tails
  4. Impact of Diet-Induced Hyperlipidemia on Pancreatic Inflammation AWARD pancan:2008-dafna-bar-sagi-phd-impact-of-diet-induced-hyperlipidemia-on

Closest collaborators

The 25 strongest of 99 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. George Miller · 3 shared papers, 1 shared grant, 2015–2022 · strength 0.77
  2. Rafael Winograd · 3 shared papers, 2021–2025 · strength 0.55
  3. Shohei Koide · 1 shared grant, 2022 · strength 0.52
  4. Kwok Kin Wong · 1 shared grant, 2022 · strength 0.52
  5. Craig Patrick Ramirez · 1 shared grant, 2022 · strength 0.52
  6. Alec C. Kimmelman · 3 shared papers, 2020–2026 · strength 0.51
  7. Emma Kurz · 3 shared papers, 2021–2025 · strength 0.46
  8. Anthony M Sorrentino · 2 shared papers, 2025–2026 · strength 0.44
  9. Laura Antonucci · 2 shared papers, 2025–2026 · strength 0.38
  10. Andrew M. Lowy · 2 shared papers, 2025–2026 · strength 0.38
  11. David W. Dawson · 2 shared papers, 2025–2026 · strength 0.38
  12. Michael Karin · 2 shared papers, 2025–2026 · strength 0.38
  13. Diane M. Simeone · 2 shared papers, 2021–2024 · strength 0.36
  14. Florencia M. McAllister · 3 shared papers, 2021–2023 · strength 0.34
  15. Joel Encarnación-Rosado · 2 shared papers, 2020–2026 · strength 0.32
  16. Keisuke Yamamoto · 2 shared papers, 2020–2026 · strength 0.32
  17. Madeleine M. LaRue · 2 shared papers, 2020–2022 · strength 0.27
  18. Douglas E. Biancur · 1 shared paper, 2026 · strength 0.24
  19. Koelina Ganguly · 1 shared paper, 2026 · strength 0.24
  20. Richard Possemato · 1 shared paper, 2026 · strength 0.24
  21. Elaine Y. Lin · 1 shared paper, 2026 · strength 0.24
  22. Michael Anthony Hollingsworth · 1 shared paper, 2026 · strength 0.24
  23. Paul M. Grandgenett · 1 shared paper, 2026 · strength 0.24
  24. Mitsuhiro Fujishiro · 1 shared paper, 2026 · strength 0.24
  25. Powel H. Brown · 2 shared papers, 2021–2023 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.